The purpose of this study was to assess the safety and efficacy of Cotrifazid to treat
uncomplicated resistant malaria and to compare the outcome with mefloquine or
quinine+sulfadoxine/pyrimethamine (SP)
Phase:
Phase 2
Details
Lead Sponsor:
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland Policlinique Médicale Universitaire
Collaborators:
Papua New Guinea Institute of Medical Research Swiss Tropical & Public Health Institute